［1］ Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2022［J］. CA Cancer J Clin， 2022， 72： 7- 33.
［2］ Reig M， Forner A， Rimola J， et al. BCLC strategy for prognosis prediction and treatment recommendation： the 2022 update［J］. J Hepatol， 2022， 76： 681- 693.
［3］ Qian K，Zhang F，Allison SK，et al. Image- guided locoregional non- intravascular interventional treatments for hepatocellular carcinoma： current status［J］. J Interv Med， 2021， 4： 1- 7.
［4］ Kudo M，Matsui O，Izumi N，et al. Transarterial chemoembolization failure/refractoriness： JSH- LCSGJ criteria 2014 update［J］. Oncology， 2014， 87： 22- 31.
［5］ Cheng AL，Amarapurkar D，Chao Y，et al. Re- evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma： consensus recommendations and review by an International Expert Panel［J］. Liver Int， 2014， 34： 174- 183.
［6］ Raoul JL，Gilabert M，Piana G. How to define transarterial chemo- embolization failure or refractoriness： a European perspective［J］. Liver Cancer， 2014， 3： 119- 124.
［7］ 仲斌演，王万胜，朱海东． 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识［J］． 介入放射学杂志， 2022， 31：1039- 1044．
［8］ Kudo M， Han KH， Ye SL， et al. A changing paradigm for the treatment of intermediate- stage hepatocellular carcinoma： Asia- Pacific primary liver cancer expert consensus statements［J］. Liver Cancer， 2020， 9： 245- 260.
［9］ Hsu SJ，Xu X，Chen MP，et al. Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in advanced hepatocellular carcinoma patients with failed or unsuitability for transarterial chemoembolization［J］. Acad Radiol， 2021， 28： S157- S166.
［10］ Ikeda M， Mitsunaga S， Shimizu S， et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization［J］. J Gastroenterol， 2014， 49： 932- 940.
［11］ Kodama K， Kawaoka T， Aikata H， et al. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status［J］. J Gastroenterol Hepatol， 2018， 33： 1780- 1786.
［12］ Zheng L， Fang S， Wu F， et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE- refractory hepatocellular carcinoma： a retrospective study［J］. Front Mol Biosci， 2020， 7： 609322.
［13］ Lin LW， Ke K， Yan LY， et al. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death- 1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization［J］. Front Oncol， 2023， 13： 1178428.
［14］ Liu K， Min XL， Peng J， et al. The changes of HIF- 1α and VEGF expression after TACE in patients with hepatocellular carcinoma［J］. J Clin Med Res， 2016， 8： 297- 302.
［15］ Cheng X， Li J， Feng L， et al. The role of hypoxia- related genes in TACE- refractory hepatocellular carcinoma： exploration of prognosis， immunological characteristics and drug resistance based on onco- multi- OMICS approach［J］. Front Pharmacol， 2022， 13： 1011033.
［16］ Li W， Kong S， Su J， et al. Efficacy of transcatheter arterial chemoembolization combined with sorafenib in inhibiting tumor angiogenesis in a rabbit VX2 liver cancer model［J］. J Interv Med， 2020， 3： 27- 33.
［17］ Kudo M， Finn RS， Qin S， et al. Lenvatinib versus sorafenib in first- line treatment of patients with unresectable hepatocellular carcinoma： a randomised phase 3 non- inferiority trial［J］. Lancet， 2018， 391： 1163- 1173.
［18］ Ferrara N. Vascular endothelial growth factor： basic science and clinical progress［J］. Endocr Rev， 2004， 25： 581- 611.
［19］ Shimose S， Kawaguchi T， Tanaka M， et al. Lenvatinib prolongs the progression- free survival time of patients with intermediate- stage hepatocellular carcinoma refractory to transarterial chemoembolization： a multicenter cohort study using data mining analysis［J］. Oncol Lett， 2020， 20： 2257- 2265.
［20］ Yi C， Chen L， Lin Z， et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti- programmed cell death- 1 in HCC［J］. Hepatology， 2021， 74： 2544- 2560.
［21］ Si T， Huang Z， Khorsandi SE， et al. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma： a systematic review with meta- analysis［J］. Front Bioeng Biotechnol， 2022， 10： 1010824.
［22］ Zhang TQ，Geng ZJ，Zuo MX，et al. Camrelizumab（a PD- 1 inhibitor） plus apatinib（an VEGFR- 2 inhibitor） and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C（TRIPLET）： a phase Ⅱ study［J］. Signal Transduct Target Ther， 2023， 8： 413.
［23］ Liu B， Zhu X， Gao S， et al. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post- transarterial chemoembolization for unresectable hepatocellular carcinoma［J］. J Interv Med， 2019， 2： 91- 96.
［24］ Zhu H，Shan Y，Ge K，et al. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy［J］. Cell Oncol（Dordr）， 2020， 43： 1203- 1214.
［25］ Zhao Y，Lai J，Liang R，et al. Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma［J］. J Interv Med， 2019， 2： 78- 83.
［26］ Zhu HD，Li HL，Huang MS，et al. Transarterial chemoembolization with PD- （L）1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma（CHANCE001）［J］. Signal Transduct Target Ther， 2023， 8： 58.
［27］ Hatooka M，Kawaoka T，Aikata H，et al. Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization［J］. Anticancer Res， 2016， 36： 3523- 3529.